Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rozanolixizumab (Primary)
  • Indications Myasthenia gravis
  • Focus Registrational; Therapeutic Use
  • Acronyms MycarinG study
  • Sponsors UCB Biopharma

Most Recent Events

  • 20 Jun 2025 According to an UCB media release, company will present crucial data focusing on the quality of life in patients with gMG treated with rozanolixizumab from this study at Congress of the European Academy of Neurology (EAN) in Helsinki, Finland, June 21-24, 2025.
  • 03 Apr 2025 According to an UCB media release, data from post-hoc analysis of this study will be presented at American Academy of Neurology (AAN) meeting, San Diego California, April 5- 9, 2025.
  • 02 Apr 2025 According to an UCB media release, injection therapy Rystiggo (rozanolixizumab-noli) has been granted regulatory approval in Canada for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) proteins. This approval of Rystiggo was supported by data from the Phase 3 MycarinG trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top